Acoramidis

BridgeBio, founded in 2015, has two products on the market and another awaiting FDA decision by November. The company is spinning out assets into new entities, discontinuing a gene therapy program, and focusing on late-stage programs in transthyretin amyloid cardiomyopathy and achondroplasia. BridgeBio aims to have six approved products by its tenth birthday, with a focus on commercializing its later-stage pipeline. The company’s success hinges on the approval and market performance of acoramidis for ATTR-CM and infigratinib for achondroplasia.